Cephalalgia

Papers
(The H4-Index of Cephalalgia is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution150
Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults101
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study73
Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia69
Isolated intracranial hypertension associated with COVID-1965
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention64
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial59
Real-world effectiveness and tolerability of erenumab: A retrospective cohort study58
Migraine therapeutics differentially modulate the CGRP pathway57
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine56
Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients53
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients53
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis52
The migraineur’s brain networks: Continuous resting state fMRI over 30 days52
The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study51
Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study50
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache44
Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study43
I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children41
Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study40
International Classification of Headache Disorders - ICHD-4 alpha39
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database38
No central action of CGRP antagonising drugs in the GTN mouse model of migraine38
Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: Lessons from the 1890 Russian/Asiatic flu36
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study36
Clinical, oculographic, and vestibular test characteristics of vestibular migraine35
Prevalence of neck pain in migraine: A systematic review and meta-analysis35
Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study33
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis33
Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study33
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study32
Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study32
Cortical morphological changes in chronic migraine in a Taiwanese cohort: Surface- and voxel-based analyses32
0.0884690284729